Printer Friendly

INCSTAR RECEIVES CLEARANCE TO MARKET NEW CMV-VUE ASSAY

 INCSTAR RECEIVES CLEARANCE TO MARKET NEW CMV-VUE ASSAY
 STILLWATER, Minn., Aug. 26 /PRNewswire/ -- INCSTAR Corporation


(ASE: ISR) announced today that it has been given 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its new CMV- vue(TM) assay for in-vitro diagnostic use. The new assay is a slide histochemical test used to aid in detection of active cytomegalovirus (CMV) infection in patients undergoing chemotherapy, solid organ transplantation, or in patients with AIDS.
 All components for performing the test are included in the kit, including positive and negative controls on each slide. The assay methodology provides a significantly earlier indication of an active CMV infection than traditional detection methods such as culture and serology tests. The total assay time is less than five hours, which is much faster than the conventional shell vial test which takes two days, or conventional cultures which can take several weeks.
 INCSTAR is a Minnesota-based manufacturer and distributor of high quality immunodiagnostic products for health care professionals and manufacturers. The company is an affiliate of the Italian-based Fiat Group (NYSE: FIA).
 -0- 8/26/92
 /CONTACT: Jack Falker of Swenson Falker Eilertsen, 612-371-0000; or John Booth of INCSTAR Corporation, 612-779-1700/
 (ISR) CO: INCSTAR Corporation ST: Minnesota IN: MTC SU:


KH -- MN006 -- 3481 08/26/92 12:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 26, 1992
Words:218
Previous Article:CIRCUS CIRCUS ANNOUNCES GRAND SLAM CANYON
Next Article:BELLSOUTH MARSHALS TELEPHONE TROOPS TO FIGHT HURRICANE ON TWO FRONTS
Topics:


Related Articles
GULL LABS RECEIVES FDA CLEARANCE FOR RESPIRATORY INFECTION TESTS
INCSTAR RECEIVES FDA CLEARANCE TO MARKET NEW TEST FOR INFECTIOUS MONONUCLEOSIS
T CELL SCIENCES TO MARKET TRAx(TM) CD4/CD8 WITH INCSTAR CORPORATION
INCSTAR DISCONTINUES R&D ON FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA) SYSTEM; PURSUES ALTERNATE NEW PRODUCT OPPORTUNITIES
INCSTAR RECEIVES FDA 510-K CLEARANCE TO MARKET NEW 'ACTH' DIAGNOSTIC KIT
CENTOCOR RECEIVES FDA CLEARANCE APPROVAL TO MARKET TWO DIAGNOSTIC TEST KITS
INCSTAR Receives FDA Clearance to Market Test to Determine Levels of Vitamin D in the Bloodstream
Sienna Biotech Receives FDA Clearance to Market Copalis System for Simultaneous Prenatal Diagnosis
INCSTAR Announces FDA Clearance of Tests for the Detection of Three Infectious Diseases
INCSTAR Receives Approval to Market its Test for the Detection and Monitoring of Graves' Disease in Japan

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters